Personalis (NASDAQ:PSNL) Trading 8.7% Higher – Here’s What Happened

Personalis, Inc. (NASDAQ:PSNL)’s share price rose 8.7% during trading on Thursday . The company traded as high as $10.29 and last traded at $10.32. Approximately 1,043,793 shares changed hands during trading, a decline of 40% from the average daily volume of 1,726,333 shares. The stock had previously closed at $9.49.

Wall Street Analyst Weigh In

PSNL has been the subject of a number of analyst reports. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. BTIG Research lowered their price objective on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Needham & Company LLC boosted their price objective on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Finally, Morgan Stanley lowered their price objective on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Personalis presently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Personalis Stock Up 10.7%

The stock has a fifty day moving average of $6.70 and a 200-day moving average of $8.05. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -10.27 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The firm had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.49 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. On average, equities analysts forecast that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Institutional Investors Weigh In On Personalis

Several large investors have recently modified their holdings of PSNL. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Personalis by 273.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after acquiring an additional 7,896,714 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Personalis by 1,332.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock valued at $11,531,000 after acquiring an additional 1,347,439 shares during the period. Kennedy Capital Management LLC boosted its holdings in shares of Personalis by 196.2% in the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after acquiring an additional 1,281,695 shares during the period. Aberdeen Group plc boosted its holdings in shares of Personalis by 36.1% in the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after acquiring an additional 861,948 shares during the period. Finally, ARK Investment Management LLC boosted its holdings in shares of Personalis by 11.3% in the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after acquiring an additional 802,268 shares during the period. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.